🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Multiple Myeloma
Clinical trial register · Israel

Multiple Myeloma Trials in Israel, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Israel and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2428 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:47 UTC
2428
Studies in scope
all four open statuses
1246
Recruiting now
open to new participants
455
Lead sponsors
across recruiting studies
Top sites
Jerusalem 35 Tel Aviv 34 Ramat Gan 31 Haifa 23 Petah Tikva 21
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Janssen Research & Development, LLC14 AbbVie8 Pfizer4 GlaxoSmithKline4 Celgene3
Site location
Jerusalem35 Tel Aviv34 Ramat Gan31 Haifa23 Petah Tikva21
All 16 locations
Target enrolment
to

Multiple Myeloma trials in Israel

57 of 2428 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Israel
Start
Recruiting
A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned
NCT07665450Multiple Myeloma
DrugsRamantamig·Bortezomib·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,000
Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2026-09-09
Not yet open
D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM
NCT07624513Multiple Myeloma
DrugsLinvoseltamab·Iberdomide·Melphalan·Isatuximab
Dana-Farber Cancer Institute
Phase 3
720
2026-08-24
Not yet open
ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma
NCT07247097Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
DrugsDaratumumab and Hyaluronidase-fihj·Elranatamab·Bortezomib·Lenalidomide
Massachusetts General Hospital
Phase 2
160
2026-08-01
Recruiting
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
NCT07555938Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
Hoffmann-La Roche
Phase 3
380
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2026-06-23
Recruiting
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT07518186Multiple Myeloma
DrugsJNJ-79635322·Teclistamab
Janssen Research & Development, LLC
Phase 3
700
Ashdod, Haifa, Petah Tikva, Ramat Gan, Tel Aviv
2026-05-31
Recruiting
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
NCT07409246Multiple Myeloma
AbbVie
Phase 1
127
Ramat Gan, Tel Aviv, Jerusalem
2026-02-27
Active, closed
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
NCT07266441Multiple Myeloma
DrugJNJ-79635322
Janssen Research & Development, LLC
Phase 2
168
Afula, Ashdod, Hadera, Jerusalem, Petah Tikva, Tel Aviv
2026-02-08
Recruiting
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
NCT07258511Multiple Myeloma
DrugsJNJ-79635322·Teclistamab
Janssen Research & Development, LLC
Phase 3
400
Beersheba, Haifa, Jerusalem, Ramat Gan, Ramat Poriya, Tel Aviv
2026-02-04
Recruiting
DC/MM Fusion Vaccine With BCMA CAR-T in R/R MM
NCT07377435Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
DrugsDC/MM Fusion Vaccine·Gm-Csf
David Avigan
Phase 1
25
2026-01-30
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
NCT06953960Multiple Myeloma
DrugsEtentamig·Pomalidomide·Daratumumab·Dexamethasone
AbbVie
Phase 1/2
325
Petah Tikva, Ramat Gan, Tel Aviv, Haifa, Jerusalem
2025-07-23
Recruiting
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
NCT06892522Multiple Myeloma
DrugsMezigdomide·Etentamig·Iberdomide·Carfilzomib
AbbVie
Phase 1/2
602
Petah Tikva, Beersheba, Ramat Gan, Haifa, Jerusalem
2025-06-30
Recruiting
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
NCT06799026Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
DrugsDC/MM Fusion Vaccine·Gm-Csf·Elranatamab
David Avigan
Phase 1
25
2025-01-31
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101Multiple Myeloma, Newly Diagnosed Multiple Myeloma
DrugsBelantamab mafodotin·Daratumumab·Lenalidomide·Dexamethasone
GlaxoSmithKline
Phase 3
520
Beersheba, Jerusalem, Koranit, Petah Tikva, Tel Aviv
2024-12-16
Recruiting
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
NCT06768489Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
DrugsJNJ-79635322·Pomalidomide·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 1
276
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2024-12-04
Recruiting
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
NCT06518551Myeloma, Multiple Myeloma, Refractory Multiple Myeloma
DrugsHydrocortisone Sodium Succinate·Elotuzumab·Iberdomide·Prednisolone
Omar Nadeem, MD
Phase 1/2
49
2024-11-01
Recruiting
Integrative Therapies in Multiple Myeloma
NCT06515249Multiple Myeloma
Bnai Zion Medical Center
Not applicable
300
Haifa
2024-07-15
Active, closed
Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06223516Multiple Myeloma
DrugEtentamig
AbbVie
Phase 1
60
Jerusalem, Ramat Gan, Tel Aviv
2024-06-17
Active, closed
A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT06425991Multiple Myeloma
DrugTeclistamab
Janssen Research & Development, LLC
Phase 1
108
Haifa, Jerusalem, Ramat Gan, Tel Aviv
2024-06-07
Active, closed
Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT06158841Multiple Myeloma
DrugsElotuzumab·Etentamig·Carfilzomib·Selinexor
AbbVie
Phase 3
421
Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv
2024-05-19
Recruiting
Elranatamab in R/R Multiple Myeloma
NCT06138275Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma
DrugElranatamab
Massachusetts General Hospital
Phase 2
32
2024-03-08
Recruiting
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
NCT06121843Multiple Myeloma
DrugsBMS-986393·Mezigdomide·Iberdomide·Elranatamab
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Phase 1
187
2024-02-22
Recruiting
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
NCT06152575Multiple Myeloma
DrugsElotuzumab·Elranatamab·Carfilzomib·Pomalidomide
Pfizer
Phase 3
492
Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv
2024-02-08
Active, closed
A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide
NCT06208150Multiple Myeloma
DrugsElotuzumab·Velcade·Talquetamab·Teclistamab
Janssen Research & Development, LLC
Phase 3
838
Be’er Ya‘aqov, Haifa, Petah Tikva, Ramat Gan, Tel Aviv
2024-01-22
Active, closed
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
NCT06045806Multiple Myeloma
DrugsIdecabtagene vicleucel·Fludarabine·Lenalidomide·Cyclophosphamide
Celgene
Phase 3
79
Petah Tikva, Ramat Gan, Beersheba, Tel Aviv, Haifa, Jerusalem
2023-10-16
Active, closed
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
NCT05257083Multiple Myeloma
DrugsCilta-cel·Bortezomib·Daratumumab·Fludarabine
Stichting European Myeloma Network
Phase 3
759
Jerusalem, Ramat Gan, Tel Aviv
2023-10-10
Active, closed
A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma
NCT05827016Multiple Myeloma
DrugsIberdomide·Lenalidomide
Bristol-Myers Squibb
Phase 3
1,230
Ashdod, Beer Ya'Aqov, Hadera, Haifa, Jerusalem, Petah Tikva, Ramat Gan
2023-06-22
Recruiting
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
NCT05714839Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Dexamethasone
GlaxoSmithKline
Phase 1/2
123
Beersheba, Jerusalem, Ramat Gan
2023-06-14
Recruiting
Study of Belantamab Mafodotin With Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed Multiple Myeloma
NCT05789303Multiple Myeloma, Relapse Multiple Myeloma
DrugsBelantamab mafodotin·Carfilzomib·Pomalidomide·Dexamethasone
University of Chicago
Phase 2
83
2023-05-30
Active, closed
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma
NCT05646836Multiple Myeloma
DrugsCevostamab·Tocilizumab
Genentech, Inc.
Phase 1
90
Petah Tikva, Tel Aviv
2023-03-21
Recruiting
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
NCT05650632Multiple Myeloma
DrugEtentamig
AbbVie
Phase 1
210
Petah Tikva, Jerusalem, Ramat Gan, Tel Aviv
2023-03-21
Active, closed
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
NCT05675449Multiple Myeloma
DrugsElranatamab·Carfilzomib
Pfizer
Phase 1
59
Haifa, Jerusalem, Petah Tikva
2022-12-14
Recruiting
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
NCT05623020Multiple Myeloma
DrugsElranatamab·Bortezomib·Daratumumab·Lenalidomide
Pfizer
Phase 3
1,060
Petah Tikva, Ramat Gan, Jerusalem, Beersheba, Tel Aviv
2022-11-10
Recruiting
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
NCT05552222Multiple Myeloma
DrugsTalquetamab·Teclistamab·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 3
1,590
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-10-25
Active, closed
A Study Evaluating the Efficacy and Safety of Cevostamab in Prior B Cell Maturation Antigen (BCMA)-Exposed Participants With Relapsed/Refractory Multiple Myeloma
NCT05535244Multiple Myeloma
DrugsCevostamab·Tocilizumab
Hoffmann-La Roche
Phase 1/2
90
Jerusalem, Ramat Gan, Tel Aviv
2022-10-17
Active, closed
A Study Comparing Talquetamab in Combination With Daratumumab or in Combination With Daratumumab and Pomalidomide Versus Daratumumab in Combination With Pomalidomide and Dexamethasone in Participants With Multiple Myeloma That Returns After Treatment or is Resistant to Treatment
NCT05455320Multiple Myeloma
DrugsTalquetamab·Pomalidomide·Daratumumab·Dexamethasone
Janssen Research & Development, LLC
Phase 3
864
Afula, Be’er Ya‘aqov, Hadera, Haifa, Jerusalem, Nahariya, Petah Tikva, Ramat Gan
2022-10-13
Recruiting
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
NCT05243797Multiple Myeloma
DrugsTeclistamab·Lenalidomide
European Myeloma Network B.V.
Phase 3
1,594
Beersheba, Haifa, Jerusalem, Petah Tikva, Ramat Gan, Tel Aviv
2022-09-08
Recruiting
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
NCT05137054Multiple Myeloma
DrugsNirogacestat·Cevostamab·Fianlimab·Linvoseltamab
Regeneron Pharmaceuticals
Phase 1
317
Ramat Gan, Haifa, Jerusalem
2022-08-17
Active, closed
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
NCT04975997Multiple Myeloma
DrugsIberdomide·Bortezomib·Daratumumab·Dexamethasone
Celgene
Phase 3
939
Afula, Haifa, Jerusalem, Tel Aviv, Tel Litwinsky
2022-06-23
Active, closed
Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant
NCT05317416Multiple Myeloma
DrugsElranatamab·Lenalidomide
Pfizer
Phase 3
854
Petah Tikva, Ramat Gan, Jerusalem, Haifa, Beersheba, Tel Aviv
2022-03-25
Recruiting
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
NCT05201781Multiple Myeloma
DrugCilta-cel
Janssen Research & Development, LLC
Phase 4
295
Tel Aviv
2022-03-09
Recruiting
Study of CAR-BCMA, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against BCMA in Subjects With Multiple Myeloma
NCT05243212Multiple Myeloma, Relapse Multiple Myeloma
Sheba Medical Center
Phase 1/2
75
Ramat Gan
2021-09-19
Active, closed
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
NCT04923893Multiple Myeloma
DrugsCilta-cel·Bortezomib·Fludarabine·Lenalidomide
Janssen Research & Development, LLC
Phase 3
743
Jerusalem, Ramat Gan, Tel Aviv
2021-08-19
Recruiting
A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04910568Multiple Myeloma
DrugsCevostamab·Pomalidomide·Tocilizumab·Daratumumab
Genentech, Inc.
Phase 1
186
Haifa, Tel Aviv
2021-07-26
Active, closed
A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
NCT04586426Multiple Myeloma
DrugsTalquetamab·Teclistamab
Janssen Research & Development, LLC
Phase 1/2
228
Jerusalem, Ramat Gan, Tel Aviv
2020-12-15
Active, closed
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623Multiple Myeloma
DrugsBelantamab mafodotin·Pomalidomide·Bortezomib·Dexamethasone
GlaxoSmithKline
Phase 3
302
Haifa, Jerusalem, Kfar Saba, Nahariya, Petah Tikva, Tel Aviv
2020-10-01
Active, closed
KRDI in Transplant-Eligible MM
NCT04430894Multiple Myeloma
DrugsIsatuximab·Carfilzomib·Lenalidomide·Dexamethasone
Massachusetts General Hospital
Phase 2
50
2020-07-10
Active, closed
A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma
NCT04181827Multiple Myeloma
DrugsCilta-cel·Pomalidomide·Bortezomib·Daratumumab
Janssen Research & Development, LLC
Phase 3
419
Jerusalem, Ramat Gan, Tel Aviv
2020-06-12
Active, closed
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
NCT04176718Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse, Relapse
DrugsDarzalex·Carfilzomib·Pomalidomide·Daratumumab
Andrew Yee, MD
Phase 2
44
2020-05-18
Active, closed
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047Multiple Myeloma
DrugsBelantamab mafodotin·Bortezomib·Daratumumab·Dexamethasone
GlaxoSmithKline
Phase 3
494
Tel Aviv
2020-05-07
Active, closed
A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma
NCT04133636Multiple Myeloma
DrugsCilta-cel·Bortezomib·Daratumumab·Lenalidomide
Janssen Research & Development, LLC
Phase 2
208
Ramat Gan, Tel Aviv
2019-11-07
Active, closed
A Study Designed to Evaluate the Safety and Efficacy of Venetoclax Plus Dexamethasone (VenDex) Compared With Pomalidomide Plus Dexamethasone (PomDex) in Participants With t(11;14)-Positive Relapsed or Refractory Multiple Myeloma.
NCT03539744Multiple Myeloma
DrugsPomalidomide·Venetoclax·Dexamethasone
AbbVie
Phase 3
265
Haifa, Jerusalem, Ashdod, Beersheba, Ramat Gan, Tel Aviv, Petah Tikva
2018-10-22
Active, closed
A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma
NCT03314181Multiple Myeloma
DrugsBortezomib·Daratumumab·Venetoclax·Dexamethasone
AbbVie
Phase 2
156
2018-04-02
Active, closed
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
NCT02952508Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugCLR 131
Cellectar Biosciences, Inc.
Phase 2
120
Jerusalem
2017-07-26
Active, closed
A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma
NCT02773030Multiple Myeloma
DrugsDarzalex·Velcade·Iberdomide·Carfilzomib
Celgene
Phase 1/2
466
Jerusalem, Tel Aviv, Tel Litwinsky
2016-10-14
Active, closed
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65
NCT01208662Multiple Myeloma
DrugsVelcade·Bortezomib·Lenalidomide·Dexamethasone
Paul Richardson, MD
Phase 3
729
2010-09
Active, closed
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00602641Multiple Myeloma
DrugsThalidomide·Melphalan·Prednisone·Lenalidomide
National Cancer Institute (NCI)
Phase 3
306
Haifa, Jerusalem
2008-02-29
Active, closed
Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma
NCT00378105Multiple Myeloma
DrugsBortezomib·Lenalidomide·Dexamethasone
Dana-Farber Cancer Institute
Phase 1/2
68
2006-09
Rows per page Showing 1–57 of 57
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with an Israeli investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-israel/condition/multiple-myeloma

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Israel and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,428 studies in total at the last sync on 26 Sep 2026, 19:47 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 57 of those studies listing the condition Multiple Myeloma.

How many Multiple Myeloma trials are recruiting in Israel?

26 of the 57 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:47 UTC sync. A further 2 have not yet opened recruitment, 29 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Multiple Myeloma), 57 studies
PhaseStudiesRecruitingShare
Phase 325943.9%
Phase 112821.1%
Phase 1/29515.8%
Phase 29215.8%
Not applicable111.8%
Phase 4111.8%

Most active sponsors

Lead sponsors with the most studies (Multiple Myeloma)
Lead sponsorStudiesRecruiting
Janssen Research & Development, LLC146
AbbVie84
GlaxoSmithKline42
Pfizer42
Celgene30
Massachusetts General Hospital31
Dana-Farber Cancer Institute20
David Avigan22
Genentech, Inc.21
Hoffmann-La Roche21
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.